This article requires a subscription to view the full text. You may purchase access to this article or login to access your subscription using the links below.
Abstract
Summary: The dramatic intertumoral and intratumoral heterogeneity in glioblastoma represents a formidable obstacle to finding effective combination targeted therapy for each individual patient. The article by Wang and colleagues in this issue of Cancer Discovery adds to a growing body of literature that points to these diverse aberrant genomes coalescing onto a very limited number of cellular states, reviving the hope of eventually identifying and therapeutically targeting just a few central gene-regulatory targets in most gliomas.
See related article by Wang et al., p. 1708.
Footnotes
Cancer Discov 2019;9:1650–2
- ©2019 American Association for Cancer Research.
Log in using your username and password
Purchase access
Volume 9, Issue 12
